Myeloid neoplasm with prominent eosinophilia and PDGFRA rearrangement treated with imatinib mesylate |
| |
| Authors: | Mathias Rathe MD Thomas Kielsgaard Kristensen PhD Michael Boe Møller MD DMSc Niels LT Carlsen MD DMSc |
| |
| Institution: | 1. Department of Pediatric Hematology and Oncology, H.C. Andersen Children's Hospital, Odense University Hospital, Odense, Denmark;2. Department of Pathology, Odense University Hospital, Odense, Denmark |
| |
| Abstract: | The FIP1L1–PDGFRA fusion gene is the most frequent genetic aberration in myeloid neoplasms associated with eosinophilia and abnormalities of PDGFRA, PDGFRB, or FGFR1. Affected patients in adult populations are very sensitive to imatinib therapy. Pediatric cases are rare and so far only one case of FIP1L1–PDGFRA positive disease has been reported. We report a 2‐year‐old female with a myeloid neoplasm associated with eosinophilia and rearrangement of PDGFRA. Treatment with imatinib resulted in complete and durable clinical, hematological, and molecular remission within 3 months after starting treatment. Pediatr Blood Cancer. 2010;55:730–732. © 2010 Wiley‐Liss, Inc. |
| |
| Keywords: | eosinophilia FIP1L1– PDGFRA pediatric hematology/oncology tyrosine kinase tyrosine kinase inhibitor |
|
|
